~~<i id='DC9280E936'><strike id='DC9280E936'><tt id='DC9280E936'><pre id='DC9280E936'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

knowledge

author：fashion 2025-10-01 02:15:54 - browse：62

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： HCA discloses massive data breach affecting 11 million patients

focus

hotspot

explore

entertainment

hotspot

entertainment

Stainingrevealsdifferentimmunecellsinahealthyhumancolon.CourtesyOliviaNewton-JohnCancerResearchinsti

WSS

Beach reads and more: STAT's 2023 summer book list

Bulgari apologizes to China for listing Taiwan as a country after online backlash

Was Amgen transparent enough on FDA's concern on cancer drug?

Retired US general questions alleged Putin, Prigozhin meeting

How the political right came to back psychedelics to treat trauma

Sana to lay off nearly a third of staff, de

leisure time

knowledge

focus

Dobbs anniversary: the lost opportunity of abortion as health care

Chan Zuckerberg Biohub Chicago to focus on inflammation

Cancer drug shortages should be causing more outrage

Colorectal cancer study finds potential in overlooked immune cell

Medicare details structure of new drug price negotiation program

Oak trusses raised to roof of fire

Continuity nursing helped my family in our darkest PICU moments

FDA rejects Alnylam's heart disease treatment over insufficient data

BioMarin wins approval for gene therapy to treat hemophilia A

VC firm General Catalyst wants to buy a health system

hotspot

DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed

HCA discloses massive data breach affecting 11 million patients

Analysis of telehealth claims data suggest service duplication

Living with Fabry disease, a condition that causes chronic pain

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Petition to FDA: Get the lead out of consumer hair dyes

explore

entertainment

hotspot

entertainment